Factor VIII inhibitors: Risk factors and methods for prevention and immune modulation

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 2, 2009, Pages 114-124

  Zhang, Ai Hong ^a   Skupsky, Jonathan ^a   Scott, David W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

FVIII; Hemophilia inhibitors; Immune tolerance; Immunogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAKED DNA; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CELL SURVIVAL; CELL TRANSPLANTATION; CONTINUOUS INFUSION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE TRANSFER; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; NONVIRAL GENE THERAPY; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TISSUE TRANSPLANTATION; X CHROMOSOME;

ANIMALS; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MICE; RISK FACTORS;

EID: 70349310353     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8122-5     Document Type: Review

References (87)

1. LW Hoyer 1994 Hemophilia A N Engl J Med 330 38 47 8259143 10.1056/NEJM199401063300108 1:STN:280:DyaK2c%2FotFyktQ%3D%3D (Pubitemid 24018616)
2. PJ Lenting JA van Mourik K Mertens 1998 The life cycle of coagulation factor VIII in view of its structure and function Blood 92 3983 3996 9834200 1:CAS:528:DyaK1cXnslylsrw%3D
3. S Dasgupta Y Repesse J Bayry AM Navarrete B Wootla S Delignat T Irinopoulou C Kamate JM Saint-Remy M Jacquemin PJ Lenting A Borel-Derlon SV Kaveri S Lacroix-Desmazes 2007 VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors Blood 109 610 612 16985172 10.1182/blood-2006-05-022756 1:CAS:528:DC%2BD2sXivVyrsro%3D (Pubitemid 46105959)
4. PC Spiegel Jr. M Jacquemin JM Saint-Remy BL Stoddard KP Pratt 2001 Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII Blood 98 13 19 11418455 10.1182/blood.V98.1.13 1:CAS:528:DC%2BD3MXkvFSmur4%3D
5. J Astermark 2006 Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors Haemophilia 12 Suppl 6 8 13 17123388 10.1111/j.1365-2516.2006.01360.x 1:CAS:528:DC%2BD28XhtlGiu7rK (Pubitemid 44741497)
6. GC White D DiMichele K Mertens C Negrier IR Peake C Prowse R Schwaab A Yoshioka J Ingerslev 1999 Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Thromb Haemost 81 462 10102478 1:CAS:528:DyaK1MXhvFWlt7k%3D
7. S Lacroix-Desmazes J Bayry N Misra MP Horn S Villard A Pashov N Stieltjes R d'Oiron JM Saint-Remy J Hoebeke MD Kazatchkine J Reinbolt D Mohanty SV Kaveri 2002 The prevalence of proteolytic antibodies against factor VIII in hemophilia A N Engl J Med 346 662 667 11870243 10.1056/NEJMoa011979 1:CAS:528: DC%2BD38XhsFOjsr0%3D (Pubitemid 34815870)
8. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV (1999) Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 5:1044-1047
9. S Lacroix-Desmazes AM Navarrete S Andre J Bayry SV Kaveri S Dasgupta 2008 Dynamics of factor VIII interactions determine its immunological fate in hemophilia A Blood 112 2 240 249 18469198 10.1182/blood-2008-02-124941 1:CAS:528:DC%2BD1cXos1Cisbc%3D
10. P Matzinger 2002 The danger model: a renewed sense of self Science 296 301 305 11951032 10.1126/science.1071059 1:CAS:528:DC%2BD38XjtVWiurk%3D (Pubitemid 34303674)
11. S Dasgupta AM Navarrete S Delignat B Wootla S Andre V Nagaraja S Lacroix-Desmazes SV Kaveri 2007 Immune response against therapeutic factor VIII in hemophilia A patients-a survey of probable risk factors Immunol Lett 110 23 28 17467813 10.1016/j.imlet.2007.03.006 1:CAS:528:DC%2BD2sXkvFGgtrk%3D (Pubitemid 46678229)
12. J Gitschier WI Wood TM Goralka KL Wion EY Chen DH Eaton GA Vehar DJ Capon RM Lawn 1984 Characterization of the human factor VIII gene Nature 312 326 330 6438525 10.1038/312326a0 1:CAS:528:DyaL2MXktVyksw%3D%3D (Pubitemid 15209308)
13. WI Wood DJ Capon CC Simonsen DL Eaton J Gitschier B Keyt PH Seeburg DH Smith P Hollingshead KL Wion, et al. 1984 Expression of active human factor VIII from recombinant DNA clones Nature 312 330 337 6438526 10.1038/312330a0 1:CAS:528:DyaL2MXntlCnsQ%3D%3D (Pubitemid 15209309)
14. JJ Toole JL Knopf JM Wozney LA Sultzman JL Buecker DD Pittman RJ Kaufman E Brown C Shoemaker EC Orr, et al. 1984 Molecular cloning of a cDNA encoding human antihaemophilic factor Nature 312 342 347 6438528 10.1038/312342a0 1:CAS:528:DyaL2MXksV2isrw%3D (Pubitemid 15209311)
15. AI Wacey G Kemball-Cook HH Kazazian SE Antonarakis R Schwaab P Lindley EG Tuddenham 1996 The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS Nucleic Acids Res 24 100 102 8594555 10.1093/nar/24.1.100 1:CAS:528:DyaK28XnsV2rtQ%3D%3D (Pubitemid 26085744)
16. SE Antonarakis JP Rossiter M Young J Horst P de Moerloose SS Sommer RP Ketterling HH Kazazian Jr C Negrier C Vinciguerra J Gitschier M Goossens E Girodon N Ghanem F Plassa JM Lavergne M Vidaud JM Costa Y Laurian SW Lin SR Lin MC Shen D Lillicrap SA Taylor S Windsor SV Valleix K Nafa Y Sultan M Delpech CL Vnencak-Jones JA Phillips 3rd RC Ljung E Koumbarelis A Gialeraki T Mandalaki PV Jenkins PW Collins KJ Pasi A Goodeve I Peake FE Preston M Schwartz E Scheibel J Ingerslev DN Cooper DS Millar VV Kakkar F Giannelli JA Naylor EF Tizzano M Baiget M Domenech C Altisent J Tusell M Beneyto JI Lorenzo C Gaucher C Mazurier K Peerlinck G Matthijs JJ Cassiman J Vermylen PG Mori M Acquila D Caprino H Inaba 1995 Factor VIII gene inversions in severe hemophilia A: results of an international consortium study Blood 86 2206 2212 7662970 1:CAS:528: DyaK2MXotVSht7Y%3D
17. RD Bagnall N Waseem PM Green F Giannelli 2002 Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A Blood 99 168 174 11756167 10.1182/blood.V99.1.168 1:CAS:528:DC%2BD38XivF2iuw%3D%3D (Pubitemid 34532979)
18. SS Fakharzadeh HH Kazazian Jr. 2000 Correlation between factor VIII genotype and inhibitor development in hemophilia A Semin Thromb Hemost 26 167 171 10919409 10.1055/s-2000-9819 1:CAS:528:DC%2BD3cXltFOitLs%3D
19. J Oldenburg J Schroder HH Brackmann C Muller-Reible R Schwaab E Tuddenham 2004 Environmental and genetic factors influencing inhibitor development Semin Hematol 41 82 88 14872427 10.1053/j.seminhematol.2003.11.016 1:CAS:528:DC%2BD2cXitFWnu74%3D
20. ML Liu S Nakaya AR Thompson 2002 Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses Thromb Haemost 87 273 276 11858487 1:CAS:528:DC%2BD38XhsFSnurk%3D
21. R Schwaab HH Brackmann C Meyer J Seehafer M Kirchgesser A Haack K Olek EG Tuddenham J Oldenburg 1995 Haemophilia A: mutation type determines risk of inhibitor formation Thromb Haemost 74 1402 1406 8772209 1:CAS:528: DyaK28Xjtlyitw%3D%3D
22. J Astermark 2006 Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia Haemophilia 12 Suppl 3 52 60 16683997 10.1111/j.1365-2516.2006.01261.x 1:CAS:528: DC%2BD28XovFyltb8%3D
23. MS Figueiredo F Bernardi MA Zago 1992 A novel deletion of FVIII gene associated with variable levels of FVIII inhibitor Eur J Haematol 48 152 154 1559571 1:CAS:528:DyaK38Xls1yksb0%3D
24. AC Goodeve I Williams GL Bray IR Peake 2000 Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group Thromb Haemost 83 844 848 10896236 1:CAS:528:DC%2BD3cXkslOhtb0%3D
25. J Oldenburg A Pavlova 2006 Genetic risk factors for inhibitors to factors VIII and IX Haemophilia 12 Suppl 6 15 22 17123389 10.1111/j.1365-2516.2006. 01361.x 1:CAS:528:DC%2BD28XhtlGiu7rL (Pubitemid 44741498)
26. A Goodeve 2003 The incidence of inhibitor development according to specific mutations-and treatment Blood Coagul Fibrinolysis 14 Suppl 1 S17 21 14567530 10.1097/00001721-200306001-00005 1:CAS:528:DC%2BD3sXntFyru70%3D (Pubitemid 36951877)
27. M Young H Inaba LW Hoyer M Higuchi HH Kazazian Jr. SE Antonarakis 1997 Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene Am J Hum Genet 60 565 573 9042915 1:CAS:528:DyaK2sXhvFGjtbo%3D
28. J Oldenburg J Schroder C Schmitt HH Brackmann R Schwaab 1998 Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype Thromb Haemost 79 452 453 9493612 1:CAS:528:DyaK1cXhtVeisbs%3D
29. CR Hay 1998 Factor VIII inhibitors in mild and moderate-severity haemophilia A Haemophilia 4 558 563 9873794 10.1046/j.1365-2516.1998.440558.x 1:STN:280:DyaK1M%2FptVCrsg%3D%3D
30. A Nunez-Roldan A Arnaiz-Villena G Nunez-Ollero 1979 Genetic control by the HLA region of the immune response to factor VIII in hemophilic patients C R Seances Acad Sci D 288 1719 1720 114335 1:STN:280:DyaL3c%2Fit12gtw%3D%3D
31. LE Lippert LM Fisher LB Schook 1990 Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A Thromb Haemost 64 564 568 1982196 1:STN:280:DyaK3M7psF2rtA%3D%3D
32. CR Hay W Ollier L Pepper A Cumming S Keeney AC Goodeve BT Colvin FG Hill FE Preston IR Peake 1997 HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party Thromb Haemost 77 234 237 9157572 1:CAS:528:DyaK2sXhtlCgu7g%3D
33. J Oldenburg JK Picard R Schwaab HH Brackmann EG Tuddenham E Simpson 1997 HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII Thromb Haemost 77 238 242 9157573 1:CAS:528:DyaK2sXhtlCgu7k%3D
34. J Astermark J Oldenburg J Carlson A Pavlova K Kavakli E Berntorp AK Lefvert 2006 Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A Blood 108 3739 3745 16926287 10.1182/blood-2006-05-024711 1:CAS:528:DC%2BD28Xht1Kgs7%2FF (Pubitemid 44864553)
35. G Bouma JB Crusius M Oudkerk Pool JJ Kolkman BM von Blomberg PJ Kostense MJ Giphart GM Schreuder SG Meuwissen AS Pena 1996 Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease Scand J Immunol 43 456 463 8668926 10.1046/j.1365-3083.1996.d01-65.x 1:CAS:528:DyaK28XislOmsr8%3D
36. AG Wilson N de Vries F Pociot FS di Giovine LB van der Putte GW Duff 1993 An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles J Exp Med 177 557 560 8426126 10.1084/jem.177.2.557 1:CAS:528:DyaK3sXnvFWgtw%3D%3D
37. Y Zhou R Giscombe D Huang AK Lefvert 2002 Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene J Rheumatol 29 317 320 11838849 1:CAS:528:DC%2BD38XhsF2iu7w%3D
38. DR Huang YH Zhou SQ Xia L Liu R Pirskanen AK Lefvert 1999 Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease J Neuroimmunol 94 82 87 10376939 10.1016/S0165-5728(98)00228-8 1:CAS:528:DyaK1MXmtVGnug%3D%3D (Pubitemid 29071246)
39. J Astermark J Oldenburg A Pavlova E Berntorp AK Lefvert 2006 Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A Blood 107 3167 3172 16380445 10.1182/blood-2005-09-3918 1:CAS:528:DC%2BD28Xjs1Oksrw%3D
40. J Astermark E Berntorp GC White BL Kroner 2001 The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients Haemophilia 7 267 272 11380630 10.1046/j.1365-2516.2001.00510.x 1:CAS:528:DC%2BD3MXnsFWnsr4%3D (Pubitemid 32471960)
41. JI Lorenzo A Lopez C Altisent JA Aznar 2001 Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age Br J Haematol 113 600 603 11380444 10.1046/j.1365-2141.2001.02828.x 1:CAS:528: DC%2BD3MXkvFehsLc%3D (Pubitemid 32524377)
42. SC Gouw JG van der Bom G Auerswald CE Ettinghausen U Tedgard HM van den Berg 2007 Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study Blood 109 4693 4697 17218379 10.1182/blood-2006-11-056317 1:CAS:528:DC%2BD2sXmt1OgtLk%3D (Pubitemid 46827760)
43. E Santagostino ME Mancuso A Rocino G Mancuso MG Mazzucconi A Tagliaferri M Messina PM Mannucci 2005 Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study Br J Haematol 130 422 427 16042693 10.1111/j.1365-2141.2005.05605.x 1:CAS:528:DC%2BD2MXhtVWjsLjJ (Pubitemid 43899592)
44. A Sharathkumar D Lillicrap VS Blanchette M Kern J Leggo AM Stain L Brooker MD Carcao 2003 Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A J Thromb Haemost 1 1228 1236 12871324 10.1046/j.1538-7836.2003.00230.x 1:CAS:528:DC%2BD2cXktFOisr4%3D
45. C von Auer J Oldenburg M von Depka C Escuriola-Ettinghausen K Kurnik H Lenk I Scharrer 2005 Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates Ann N Y Acad Sci 1051 498 505 10.1196/annals.1361.094 (Pubitemid 41363770)
46. HM van den Berg G Roosendaal J Voorberg EP Mauser-Bunschoten 1999 Inhibitor development in a multitransfused patient with severe haemophilia A Thromb Haemost 82 151 152 10456472
47. M Koestenberger W Raith W Muntean 2000 High titre inhibitor after continuous factor VIII administration for surgery in a young infant Haemophilia 6 120 10781202 10.1046/j.1365-2516.2000.00377.x 1:STN:280:DC%2BD3c3ksVSnsA%3D%3D (Pubitemid 30166837)
48. BM Reipert PM van Helden HP Schwarz C Hausl 2007 Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors Br J Haematol 136 12 25 17222196 10.1111/j.1365-2141.2006.06359.x 1:CAS:528:DC%2BD2sXisVKisbk%3D (Pubitemid 44912584)
49. LM Aledort 2004 Is the incidence and prevalence of inhibitors greater with recombinant products? Yes J Thromb Haemost 2 861 862 15140115 10.1111/j.1538-7836.2004.00731.x 1:STN:280:DC%2BD2c3kt1eqsw%3D%3D (Pubitemid 40185728)
50. JM Lusher 2004 Is the incidence and prevalence of inhibitors greater with recombinant products? No J Thromb Haemost 2 863 865 15140116 10.1111/j.1538-7836.2004.00729.x 1:STN:280:DC%2BD2c3kt1eqsA%3D%3D (Pubitemid 40192490)
51. PM Mannucci 2006 Need for randomized trials in hemophilia J Thromb Haemost 4 501 502 16460428 10.1111/j.1538-7836.2006.01852.x 1:STN:280: DC%2BD28%2Fns1ekuw%3D%3D
52. J Goudemand C Rothschild V Demiguel C Vinciguerrat T Lambert H Chambost A Borel-Derlon S Claeyssens Y Laurian T Calvez 2006 Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A Blood 107 46 51 16166584 10.1182/blood-2005-04-1371 1:CAS:528:DC%2BD28XhsVGhuw%3D%3D (Pubitemid 43054971)
53. T Calvez Y Laurian J Goudemand 2008 Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies J Thromb Haemost 6 390 392 18036187 1:CAS:528:DC%2BD1cXjtVKksLw%3D
54. CE Ettingshausen W Kreuz 2006 Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development Haemophilia 12 Suppl 6 102 106 17123402 10.1111/j.1365-2516.2006.01373.x (Pubitemid 44741510)
55. EA Chalmers SA Brown D Keeling R Liesner M Richards D Stirling A Thomas V Vidler MD Williams D Young 2007 Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A Haemophilia 13 149 155 17286767 10.1111/j.1365-2516.2006.01418.x 1:STN:280:DC%2BD2s%2FovFWlsQ%3D%3D (Pubitemid 46237946)
56. I Scharrer HJ Ehrlich 2004 Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges Haemophilia 10 197 198 14962213 10.1111/j.1365-2516.2004.00887.x 1:STN:280:DC%2BD2c%2FntlOqsQ%3D%3D
57. S Dasgupta AM Navarrete J Bayry S Delignat B Wootla S Andre O Christophe M Nascimbeni M Jacquemin L Martinez-Pomares TB Geijtenbeek A Moris JM Saint-Remy MD Kazatchkine SV Kaveri S Lacroix-Desmazes 2007 A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes Proc Natl Acad Sci U S A 104 8965 8970 17502612 10.1073/pnas. 0702120104 1:CAS:528:DC%2BD2sXmt1Wmu7w%3D (Pubitemid 47175420)
58. AS De Groot DW Scott 2007 Immunogenicity of protein therapeutics Trends Immunol 28 482 490 17964218 10.1016/j.it.2007.07.011 (Pubitemid 350087812)
59. VS Purohit CR Middaugh SV Balasubramanian 2006 Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice J Pharm Sci 95 358 371 16372314 10.1002/jps.20529 1:CAS:528:DC%2BD28XhsFeks70%3D (Pubitemid 43241978)
60. K Pfistershammer J Stockl J Siekmann PL Turecek HP Schwarz BM Reipert 2006 Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells Thromb Haemost 96 309 316 16953272 1:CAS:528:DC%2BD28XhtVOmt7nM
61. Lozier JN ZP (2005) Mapping of genes that control the antibody response to human FVIII in mice. Blood (ASH Annual Meeting Abstracts) 106:Abstract 1888
62. J Skupsky JN Lozier R Donahue M Metzger A Azimzadeh R Pierson D Scott 2007 Immunogenicity of human factor VIII in rhesus and cynomolgus monkeys Blood (ASH Annual Meeting Abstracts) 110 3148
63. KA High 2007 Update on progress and hurdles in novel genetic therapies for hemophilia Hematology Am Soc Hematol Educ Program 2007 466 472
64. VS Purohit K Ramani R Sarkar HH Kazazian Jr. SV Balasubramanian 2005 Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex J Biol Chem 280 17593 17600 15728582 10.1074/jbc.M500163200 1:CAS:528:DC%2BD2MXjsl2itLk%3D (Pubitemid 41388993)
65. HZ Miao N Sirachainan L Palmer P Kucab MA Cunningham RJ Kaufman SW Pipe 2004 Bioengineering of coagulation factor VIII for improved secretion Blood 103 3412 3419 14726380 10.1182/blood-2003-10-3591 1:CAS:528:DC%2BD2cXjslKgtrg%3D (Pubitemid 38525672)
66. JS Powell MV Ragni GC White 2nd JM Lusher C Hillman-Wiseman TE Moon V Cole S Ramanathan-Girish H Roehl N Sajjadi DJ Jolly D Hurst 2003 Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion Blood 102 2038 2045 12763932 10.1182/blood-2003-01-0167 1:CAS:528:DC%2BD3sXntlKku7k%3D (Pubitemid 37122377)
67. DA Roth NE Tawa Jr. JM O'Brien DA Treco RF Selden 2001 Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A N Engl J Med 344 1735 1742 11396439 10.1056/NEJM200106073442301 1:CAS:528:DC%2BD3MXkslKqsbw%3D (Pubitemid 32497027)
68. CS Manno AJ Chew S Hutchison PJ Larson RW Herzog VR Arruda SJ Tai MV Ragni A Thompson M Ozelo LB Couto DG Leonard FA Johnson A McClelland C Scallan E Skarsgard AW Flake MA Kay KA High B Glader 2003 AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood 101 2963 2972 12515715 10.1182/blood-2002-10-3296 1:CAS:528:DC%2BD3sXjtFCqsbY%3D (Pubitemid 36857981)
69. CS Manno GF Pierce VR Arruda B Glader M Ragni JJ Rasko MC Ozelo K Hoots P Blatt B Konkle M Dake R Kaye M Razavi A Zajko J Zehnder PK Rustagi H Nakai A Chew D Leonard JF Wright RR Lessard JM Sommer M Tigges D Sabatino A Luk H Jiang F Mingozzi L Couto HC Ertl KA High MA Kay 2006 Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response Nat Med 12 342 347 16474400 10.1038/nm1358 1:CAS:528: DC%2BD28XitVGnt78%3D (Pubitemid 43355084)
70. A Follenzi D Benten P Novikoff L Faulkner S Raut S Gupta 2008 Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice J Clin Invest 118 935 945 18274668 1:CAS:528:DC%2BD1cXivFems70%3D
71. FA Bontempo JH Lewis TJ Gorenc JA Spero MV Ragni JP Scott TE Starzl 1987 Liver transplantation in hemophilia A Blood 69 1721 1724 3107632 1:STN:280:DyaL2s3hsVGguw%3D%3D
72. JH Lewis FA Bontempo JA Spero MV Ragni TE Starzl 1985 Liver transplantation in a hemophiliac N Engl J Med 312 1189 1190 3920523 1:STN:280:DyaL2M7mtlKmtg%3D%3D
73. RT Barrow JF Healey D Gailani D Scandella P Lollar 2000 Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules Blood 95 564 568 10627463 1:CAS:528:DC%2BD3cXlsFGiuw%3D%3D
74. DB Brettler AD Forsberg PH Levine LM Aledort MW Hilgartner CK Kasper JM Lusher C McMillan H Roberts 1989 The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Arch Intern Med 149 1381 1385 2499293 10.1001/archinte.149.6.1381 1:STN:280:DyaL1M3nt1Cmuw%3D%3D (Pubitemid 19163535)
75. AE Morrison CA Ludlam C Kessler 1993 Use of porcine factor VIII in the treatment of patients with acquired hemophilia Blood 81 1513 1520 8453098 1:STN:280:DyaK3s3gtVGisg%3D%3D
76. HH Brackmann J Gormsen 1977 Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder Lancet 2 933 72276 10.1016/S0140-6736(77)90871-6 1:STN:280:DyaE1c%2FjtVGisQ%3D%3D
77. HH Brackmann J Oldenburg R Schwaab 1996 Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol' Vox Sang 70 Suppl 1 30 35 8869466 10.1111/j.1423-0410.1996.tb01346.x
78. M Carcao J St Louis MC Poon E Grunebaum S Lacroix AM Stain VS Blanchette GE Rivard 2006 Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience Haemophilia 12 7 18 16409170 10.1111/j.1365-2516.2005.01170. x 1:CAS:528:DC%2BD28XitVWjsbo%3D
79. J Qian LC Burkly EP Smith JL Ferrant LW Hoyer DW Scott CC Haudenschild 2000 Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer Eur J Immunol 30 2548 2554 11009088 10.1002/1521-4141(200009)30:9<2548::AID- IMMU2548>3.0.CO;2-H 1:CAS:528:DC%2BD3cXmsFWhurg%3D
80. J Qian M Collins AH Sharpe LW Hoyer 2000 Prevention and treatment of factor VIII inhibitors in murine hemophilia A Blood 95 1324 1329 10666206 1:CAS:528:DC%2BD3cXhtFKit70%3D
81. G Rossi J Sarkar D Scandella 2001 Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A Blood 97 2750 2757 11313267 10.1182/blood.V97.9.2750 1:CAS:528:DC%2BD3MXjtlSiu7o%3D
82. CH Miao P Ye AR Thompson DJ Rawlings HD Ochs 2006 Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice Blood 108 19 27 16507778 10.1182/blood-2005-11-4532 1:CAS:528:DC%2BD28XmsVOmt7k%3D (Pubitemid 43990608)
83. B Peng P Ye BR Blazar GJ Freeman DJ Rawlings HD Ochs CH Miao 2008 Transient blockade of the inducible costimulator pathway generates long-term tolerance for factor VIII following nonviral gene transfer into hemophilia A mice Blood 112 5 1662 1672 18574023 10.1182/blood-2008-01-128413 1:CAS:528:DC%2BD1cXhtVylu7%2FI
84. TC Lei DW Scott 2005 Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins Blood 105 4865 4870 15769892 10.1182/blood-2004-11-4274 1:CAS:528:DC%2BD2MXlsVWis70%3D (Pubitemid 40812408)
85. M El-Amine M Melo Y Kang H Nguyen J Qian DW Scott 2000 Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells J Immunol 165 5631 5636 11067919 1:CAS:528: DC%2BD3cXot1GrsLw%3D
86. MT Litzinger Y Su TC Lei N Soukhareva DW Scott 2005 Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction J Immunol 175 780 787 16002674 1:CAS:528: DC%2BD2MXlvFSjsLc%3D
87. Y Su G Carey M Marić DW Scott 2008 B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-inducible lysosomal thiol reductase-dependent pathway J Immunol 181 1153 1160 18606668 1:CAS:528:DC%2BD1cXotF2rsLY%3D